Search Bar & Filters
Found 2890 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are studying the safety, tolerability, and early clinical effects of 177Lu-BetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in adults with relapsed or refractory, locally advanced inoperable, or metastatic solid tumors. This Phase 12a trial aims to find the best dose and observe how the drug behaves in the body, as well as its preliminary impact on tumors. The study includes patients with various solid tumors such as prostate, lung, breast, ovarian, cervical, and others who have progressed after standard treatments. The study has two phases a dose escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose, followed by a dose expansion phase to evaluate initial anti-tumor activity and safety at the selected dose. Participants receive 177Lu-BetaBart intravenously every 6 weeks at increasing doses, either alone or combined with unlabeled BetaBart. Each phase includes a screening period, treatment period, and safety and long-term follow-up. The main treatment period lasts about 22 weeks, excluding long-term monitoring. During the trial, participants undergo various assessments including safety evaluations, tumor imaging, pharmacokinetics, and biochemical response measurements. Researchers monitor side effects, drug distribution, and tumor response over up to 30 weeks. The study team tracks participants health and tumor status through scans and laboratory tests to assess how well the treatment works and how safe it is. Long-term follow-up is also conducted to observe ongoing safety and effects.
Actively Recruiting
Researchers are evaluating if 18F-FAraG PET scans can detect tumors in people with esophageal cancer and predict how they respond to chemoradiation treatment. This phase 1 study aims to assess the imaging tracers ability to identify cancer and forecast complete pathologic response, along with correlations with clinical features, tissue and blood biomarkers, and survival outcomes. Participants will receive a 18F-FAraG PET scan before starting their standard treatment. About 20 minutes before the scan, they will drink water to help clear the tracer from their kidneys. The tracer is given by intravenous injection. Standard imaging will also be done before treatment begins to compare with the research scan. During the study, researchers will monitor safety and adverse events for about one year. Participants will undergo the 18F-FAraG PET scan and standard imaging to evaluate tumor detection and treatment response. Blood and tissue samples may be collected to study biomarkers. The study tracks overall and disease-free survival as part of the long-term follow-up.
Actively Recruiting
Researchers are evaluating the use of the radiopharmaceutical 18F-mFBG as an imaging agent to measure how neurodegenerative diseases affect the hearts sympathetic nervous system, particularly in people with Lewy body diseases like Parkinsons disease and Lewy body dementia. This Phase 2 study aims to compare 18F-mFBG imaging results between subjects with Lewy body disease and those with non-Lewy body neurological diseases, using historical data from healthy individuals for reference. The study addresses challenges in current imaging techniques and explores improved methods for quantifying myocardial sympathetic innervation. Participants will receive an intravenous injection of 222-370 MBq 6-10 mCi of 18F-mFBG. Imaging will be performed twice a whole-body scan from the head to the pelvis will be done 30 minutes after injection, and a static image of the chest area will be taken at 60 minutes. The study includes two groups one with known or presumed Lewy body disease and another with neurological diseases not related to Lewy bodies. Both groups undergo the same imaging procedure. Throughout the study, participants will undergo PETCT or PETMR scans to assess the extent and regional reduction of 18F-mFBG uptake in the heart and whole body. Researchers will analyze quantitative imaging data to distinguish differences between the groups. The study duration for outcome measurements is up to six months, during which participants remain clinically stable. Safety and imaging effectiveness will be carefully monitored, with the total study completion expected by December 2026.
Actively Recruiting
Researchers are evaluating the radiopharmaceutical 18F-meta-fluorobenzylguanidine 18F-mFBG as a new imaging agent to measure myocardial sympathetic innervation in stable patients with heart failure due to ischemic cardiomyopathy. This Phase 2 study focuses on adults who have a left ventricular ejection fraction of 35% or less and have implantable cardioverter-defibrillators ICDs. The study aims to compare 18F-mFBG uptake with historical imaging agents and assess differences in sympathetic innervation related to past ICD activations. Participants will receive two PET radiopharmaceuticals intravenously 18F-mFBG to assess sympathetic innervation and Rubidium-82 to assess myocardial blood flow. The study groups consist of patients who have experienced ICD activation within the past 12 months and those who have not. Both imaging agents will be used to examine cardiac regions for abnormalities and to quantify myocardial uptake patterns during the study. During the trial, participants will undergo PET imaging and safety monitoring for 24 hours after the administration of these agents. Researchers will collect imaging data, evaluate heart function, and monitor for any adverse or serious adverse events. The study will assess how well 18F-mFBG works compared to previous imaging methods and gather safety information over the course of participation.
Actively Recruiting
Researchers are studying the use of a 2,910 nm mid-infrared Fiber Laser UltraClear, Acclaro Medical to treat advanced perioral lines and wrinkles. The goal is to assess the lasers effectiveness for skin rejuvenation by using both superficial epidermis ablation and deeper skin layers ablative and coagulative effects. The study also aims to evaluate safety and participant satisfaction with this resurfacing treatment for photodamaged skin and wrinkles. Participants will receive up to two treatments with the UltraClear laser, spaced 6 to 8 weeks apart. These treatments focus on improving the appearance of perioral lines and wrinkles using the lasers combined superficial and deep skin effects. Following treatments, participants will have follow-up visits at 1 month and 3 months to evaluate the results and any side effects. Throughout the study, researchers will measure improvements using multiple scales, including the Fitzpatrick Wrinkling and Degree of Elastosis Scale, Physician Global Aesthetic Improvement Scale, and assessments by independent photographic reviewers. Participants will also report their own perceptions of aesthetic improvement and satisfaction. Safety and overall aesthetic outcomes will be monitored during follow-ups, with the total participation lasting through the 3 months after the final treatment.
Actively Recruiting
Researchers are evaluating advanced radiation treatment techniques, specifically stereotactic body radiation therapy SBRT, for safely delivering a strong dose of radiation to tumors in patients with head and neck squamous cell carcinoma HN SCC who are not eligible for curative treatment. The trial aims to compare local progression-free survival, pain response, symptom burden, toxicity, local control, progression-free survival, and overall survival between SBRT and traditional radiation methods. This Phase II randomized trial explores if SBRT can provide effective palliation in a shorter treatment period than conventional approaches. Participants will be randomly assigned to receive either traditional radiation therapy or SBRT. Both treatments involve radiation delivered according to schedules discussed with the study doctor. The study focuses on comparing these two radiation methods for palliation in patients with HN SCC. Treatment details, including timing and dosage, will be managed individually by the medical team. The trial runs until September 2027, with treatment and follow-up planned over about one year. During the study, participants undergo evaluations such as symptom assessments using the M. D. Anderson Symptom Inventory for head and neck cancer MDASI-HN, pain scoring, quality of life questionnaires, and clinical examinations including imaging like CT, MRI, or PETCT scans. Baseline symptoms, smoking history, and pregnancy status for women of child-bearing age are checked before randomization. Researchers will monitor symptom burden and treatment responses throughout the trial, with data collection continuing for up to one year after treatment. Informed consent and regular clinical assessments support participant safety and data accuracy throughout the study.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining 5-FluorouracilLeucovorin 5FULV with regorafenib for adults with metastatic colorectal cancer who have already tried two prior treatments. This randomized phase II trial compares this combination to a control treatment of trifluridine-tipiracil plus bevacizumab to understand if the new combination is not worse than the current option. The study aims to provide insights in the third-line treatment setting for this advanced cancer. Participants are randomly assigned in a 21 ratio to one of two treatment groups. The experimental group receives 5FULV given intravenously in 2-week cycles along with regorafenib taken orally with dose escalation weekly, following a 3-weeks-on1-week-off schedule, for up to 12 cycles or until disease progression or unacceptable side effects. The control group is given oral trifluridine-tipiracil twice daily on specified days in a 28-day cycle, combined with intravenous bevacizumab on days 1 and 15, repeated until progression, toxicity, or consent withdrawal, also up to 12 cycles. Throughout the study, participants undergo regular assessments to monitor treatment effects and side effects. Researchers measure how long the treatment controls the cancer, progression-free survival, response duration, and safety. Evaluations include clinical exams, laboratory tests, and monitoring for any adverse events. The study duration and follow-up extend up to 18 months to capture these outcomes and ensure participant safety and well-being during and after treatment.
1-10 of 2,890
1